Second carcass-eating fly species cleared by FDA for maggot wound therapy

The FDA’s recent clearance of a second carcass-eating fly species for maggot wound therapy marks a quiet but meaningful milestone in the fringe but persistent world of biotherapy. Maggot therapy, a century-old technique revived in modern medicine, involves placing disinfected fly larvae on chronic wounds to clean necrotic tissue through enzymatic digestion and antimicrobial secretions. While its advocates point to centuries of anecdotal success, robust clinical evidence remains thin—a gap that has historically kept mainstream medicine at arm’s length. Yet the FDA’s decision suggests a cautious institutional acknowledgment of its niche but enduring utility, particularly for patients with wounds unresponsive to conventional treatments. The broader significance lies in the growing intersection of ancient medical practices and regulatory acceptance. Maggot therapy, once dismissed as medieval quackery, now sits alongside other unconventional therapies gaining grudging scientific validation, from psychedelics to fecal microbiota transplants. Its persistence underscores a broader trend: the medical establishment’s reluctant tolerance for low-risk, high-reward interventions when standard options fail. The "fail-safe" concept of "bacon therapy"—a tongue-in-cheek nod to the idea that even if maggots don’t work, they won’t harm the patient—hints at the therapy’s uniquely low barrier to adoption. For clinicians treating diabetic ulcers or pressure sores, where infections can escalate rapidly, the calculus often favors even marginal benefits. Open questions remain. How will insurers handle the expanded use of a second species, given the therapy’s still-limited reimbursement landscape? Will further species clearances follow, or is this a calculated step to diversify an already niche treatment? And crucially, will new research emerge to quantify its efficacy beyond historical case studies, or will maggot therapy remain a last-resort curiosity? In an era where precision medicine dominates headlines, maggot therapy serves as a reminder of medicine’s humbler, trial-and-error roots. Its survival in the modern era reflects not just stubborn persistence, but a recognition that sometimes, the oldest solutions are the simplest—when nothing else works.